Abstract 193P
Background
Metastatic carcinoma of Gallbladder is a notoriously lethal malignancy and its treatment remains an enigma for the patient as well as for the treating oncologist. In India, it is most prevalent in the northern and north eastern states of Uttar Pradesh, Bihar, Orissa, West Bengal and Assam. We have reported here clinicoepidemiological profile of 142 patients having metastatic carcinoma of gall bladder.
Methods
The study comprised 142 GBC cases referred to the tertiary care centre in Kolkata, India during 2017-19. Detailed history and clinical examination followed by requisite investigations were done for the patients and were treated as per the existent guidelines.
Results
Out of 142 patients 116 (81.6%) were females while 26 (18.4%) were males. The mean age for females was 58 while for male 46 years. Total 18 (12.6%) patients had presented in poor general condition and were managed with best supportive care. The commonest presentations were abdominal pain (81%), weight loss (72%), obstructive jaundice (30%), ascites (27%) and anorexia (21%). The commonest site of metastasis were liver (87%), Ascites (30%), retroperitoneal lymphadenopathy (28%) and left supraclavicular lymphadenopathy (17%). Rare sites of metastasis were lung, brain and skeletal deposits.
Conclusions
Our study provided a clinicoepidemiological profile of patients having metastatic carcinoma gall bladder in North east India for the first time. Most of our patients presented or had history of gall bladder stone. We have tried to study various risk factors associated with the disease. Unfortunately a significant number of patients presents very late in our setting and due to non availability of effective chemotherapy or targeted therapy mortality remains very high. As the incidence of this malignancy is increasing it is the need of the hour to study various therapies for effective management of this malignancy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract